Doing our part in Canada's push towards self reliance in the fight against COVID-19

Vaccigen ltd is a Canadian company created to bring in all the technical and manufacturing capabilities of Ocugen Inc. from the USA to Canada. Ocugen is a global leader in Gene Therapies, Biotechnology, Vaccine research and production.

Publications

Doing our part in Canada's fight against COVID-19

Vaccigen, Ltd. is an emerging Canadian affiliate of Ocugen, Inc. Ocugen is a leader in gene therapy and committed to supporting the public health agenda with an investigational COVID-19 vaccine.

Phase 3 Results for COVAXIN Vaccine are available

Novel vaccine adjuvant used in COVAXIN was developed by National Institute of Health, USA

COVAXIN effectiveness on B.1.617 Delta variant

10,00,039

In 12 Countries

In 12 Countries

About Us

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat blindness diseases aswell as co-developing and manufacturing various vaccines. Ocugen’s Covaxin Covid-19 vaccine co-development partner, Bharat Biotech, shares phase 3, second interim results demonstrating 100% protection against severe disease including hospitalization and overall clinical efficacy of 78%. Covaxin is already given to millions of people in India and around the world.

Learn How Different Types of Covid 19 Vaccines Work

Vaccine Overview

Our vaccine works by teaching the immune system to make antibodies against the SARS-CoV-2 coronavirus.

Key Findings: Phase 3 Clinical Trial Involving 25,800 subjects

  • Protective Effect 78% All Disease
  • 65% Delta Variant*
  • AE Profile 12% Adverse Events**
  • 93% Severe Disease
  • < 0.5% Serious Adverse Events**

*Post hoc analysis    ** Placebo group

Protective Effect 78%All Disease 65%Delta Variant* 93%Severe Disease
AE Profile 12%Adverse Events** 0.5%Serious Adverse Events**

*Post hoc analysis
** Placebo group

Vaccine Overview

Our vaccine works by teaching the immune system to make antibodies against the SARS-CoV-2 coronavirus.

Key Findings: Phase 3 Clinical Trial Involving 25,800 subjects

Protective Effect

78% All Disease

65% Delta Variant

93% Severe Disease

AE Profile

12% Adverse Events**

<0.5% Serious Adverse Events**

*Post hoc analysis
**Placebo group

  • Protective Effect 78% All Disease
  • 65% Delta Variant*
  • 93% Severe Disease
  • AE Profile 12% Adverse Events**
  • < 0.5% Serious Adverse Events**

*Post hoc analysis    ** Placebo group

Scientific Advisory Board

Scientific Advisory Board

Pipeline Overview

Pipeline Overview

Cantor Fireside Chat with Ocugen (OCGN)

Cantor Fireside Chat with Ocugen (OCGN)

Publications

Preclinical Product Development

Animal Challenge Studies – Hamsters

Animal Challenge Studies – Rhesus Macaques

Human Clinical Trials – Phase I

Human Clinical Trials – Phase II

\

Covaxin Efficacy

W

Neutralization of B.1.1.28 P2 variant

Inactivated COVID-19 vaccine BBV152

Covaxin (BBV152) Vaccine Neutralizes SARS-CoV-2 Delta and Omicron variants

Disclaimer

Covaxin (BBV152) is an investigational whole-virus inactivated COVID-19 vaccine candidate, not yet approved in Canada. These links reflect published research conducted on the candidate vaccine.

Copy Rights @ 2021.